Press releases
GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.
https://geneuro.ch/data/news/PR-GeNeuro-MS-Study-Enrollment-Complete-EN-021821-VF.pdf
GeNeuro receives French state grant to accelerate research into the role of HERV proteins in COVID-19
Geneva, Switzerland, January 26, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced it has received an award from the French national research agency, ANR (Agence Nationale de Recherche), for its COVERI project focused on understanding the role of human endogenous retrovirus (HERV) proteins in the abnormal immune-inflammation or the neurological damages suffered by important subsets of COVID-19 patients.
GeNeuro: Cash position at December 31, 2020, Business Update and Outlook for 2021
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.
GeNeuro: financial information and business update for the third quarter 2020
Geneva, Switzerland, October 19, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 third quarter cash position and issued a business update.
https://geneuro.ch/data/news/GeNeuro-PR-Q3-2020-EN-101920.pdf
GeNeuro Reports 2020 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2020 at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2020 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2020-Results-ENG.pdf
GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) Present Temelimab Neurodegeneration Prevention Study at MSVirtual2020
Geneva, Switzerland, September 14, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a presentation by Professor Fredrik Piehl of the Karolinska Institutet’s Academic Specialist Center (ASC) at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting) provided the rationale and outline on the Phase 2 ProTEct-MS clinical study of temelimab initiated earlier this year.
https://geneuro.ch/data/news/GeNeuro-PR-Presentation-at-8th-ACTRIMS-ECTRIMS-2020-EN-vf.pdf